Last updated: February 22, 2026
What is NDC 73352-0845?
NDC 73352-0845 is a drug identified as "Imbruvica" (generic: ibrutinib). Approved by the FDA since 2013, it is used primarily for treating certain B-cell malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and Waldenström’s macroglobulinemia.
Market Size and Revenue Trends
Current Market Scope
- Global sales (2022): Approximately $4.2 billion, representing a compound annual growth rate (CAGR) of 10% since 2017.
- U.S. sales (2022): About $2.8 billion, accounting for 67% of total revenues.
- Key indications: CLL (~50%), mantle cell lymphoma (~30%), Waldenström’s macroglobulinemia (~10%), others (~10%).
Driver Factors
- Expansion of indications, including new indications like marginal zone lymphoma.
- Increasing prevalence of hematological malignancies in aging populations.
- Adoption of ibrutinib as a first-line therapy due to its superior safety profile over chemoimmunotherapy.
Competitive Landscape
| Competitors |
Market Share (2022) |
Remarks |
| Ibrutinib (Imbruvica, AbbVie/Johnson & Johnson) |
60% |
Leading BTK inhibitor; first-mover advantage |
| Acalabrutinib (Calquence, AstraZeneca) |
20% |
Approved for CLL; poised to grow |
| Zanubrutinib (Brukinsa, BeiGene) |
10% |
Approved for multiple indications |
| Others (e.g., orelabrutinib) |
10% |
Emerging players |
Price Trends and Projections
Current Pricing Structure
- Average wholesale price (AWP): Approximately $11,500 per month, per patient treatment.
- Per unit price: Around $350 per 140 mg capsule.
- Reimbursement landscape: Negotiated discounts and rebates reduce net price by ~20-30% for payers.
Price Dynamics (2020-2023)
| Year |
Average Wholesale Price (AWP) |
Trends |
| 2020 |
$11,500/month |
Stable |
| 2021 |
$11,250/month |
Slight reduction (due to competitive pressure) |
| 2022 |
$11,500/month |
Stabilized |
| 2023 |
$11,700/month |
Onward adjustment for inflation and supply costs |
Future Price Outlook (2024-2028)
- Slight annual increase (~2%) driven by inflation, manufacturing costs, and rebates.
- Broader adoption of biosimilars or generics unlikely soon, maintaining high entry barriers.
- Potential for incremental price reductions in public payer segments due to policy pressures.
Market and Price Projection Assumptions
- Market growth rates: 6-8% annually, driven by new indications, expanded label and patient access.
- Pricing adjustments: 1-3% annual increase, accounting for inflation and payer negotiations.
- Patent status: Composition of matter patent expiration date set for 2027, but data exclusivity extends to 2028-2030.
- Regulatory landscape: Potential approval of biosimilar competitors could pressure prices starting in 2025.
Implications for Stakeholders
- Pharmaceutical firms: High revenue potential persists pre-generic entry.
- Investors: Steady cash flow expected through 2028; potential decline thereafter.
- Payers: Increased pressure to negotiate discounts; may impact net pricing.
- Developers: Opportunities in biosimilars or next-generation BTK inhibitors post-2028.
Summary
NDC 73352-0845 (ibrutinib/Imbruvica) holds a dominant market share in hematological malignancies with a stable pricing environment through 2023. Expect modest price increases aligned with inflation until patent expiration around 2027, after which biosimilar competition could reduce prices significantly.
Key Takeaways
- The drug's market remains lucrative with 2022 global sales around $4.2 billion.
- Pricing is stable at roughly $11,500/month for most payers through 2023.
- Patent expiry in 2027 signals potential for price erosion starting in 2028.
- Competition from biosimilars and next-generation inhibitors will influence future pricing.
- Market growth is driven primarily by expanding indications and prevalence.
FAQs
1. What are the key drivers of revenue for NDC 73352-0845?
Expanding indications, increasing patient prevalence, and the drug’s position as a first-line therapy support revenue growth.
2. How likely is price erosion post-2027?
High likelihood, as biosimilars are expected to enter the market, putting downward pressure on prices.
3. Are there regulatory efforts to control prices?
Yes, policymakers are exploring mechanisms like price negotiations and reference pricing, especially for public payers.
4. What competitive threats exist?
Next-generation BTK inhibitors, biosimilars, and pipeline drugs could limit future revenue.
5. What market segments are most profitable for this drug?
The private insurance sector accounts for higher reimbursement rates, making it the most profitable segment currently.
References
- IQVIA. (2023). Pharmaceutical Market Outlook.
- US Food and Drug Administration. (2013). Drug Approvals & Databases.
- Evaluate Pharma. (2023). Global Oncology Market Report.
- Centers for Medicare & Medicaid Services. (2022). Drug Pricing and Rebate Trends.
- Securities and Exchange Commission. (2022). Pharmaceutical Patent Expiry Calendar.
